TCEAL2 (transcription elongation factor A like 2) is a transcriptional regulator with emerging roles in cancer biology. Located on chromosome X, TCEAL2 appears to function as a tumor suppressor in select cancer contexts. In renal cell carcinoma, TCEAL2 expression is downregulated compared to normal kidney tissue, and restoration of TCEAL2 expression inhibits cell proliferation and induces cell cycle arrest in S phase 1. The gene has been identified as a differentially regulated target of CREB1 transcription factor during gastric cancer progression 2, suggesting involvement in carcinogenic regulatory networks. TCEAL2 serves as a prognostic biomarker in colon adenocarcinoma, where decreased expression correlates with better prognosis as part of a sphingolipid metabolism-associated risk model 3. In breast cancer, TCEAL2 is associated with doxorubicin resistance mechanisms 4. Additionally, TCEAL2-ALK fusion variants have been identified as actionable driver mutations in non-small cell lung carcinoma, with patients harboring TCEAL2-ALK fusions responding favorably to ALK tyrosine kinase inhibitor alectinib treatment 5. In ovarian cancer, elevated TCEAL2 expression associates with poor prognosis 6. These findings suggest TCEAL2's pleiotropic roles: tumor-suppressive in renal cell carcinoma, prognostically relevant in multiple cancers, and therapeutically targetable when fused with ALK.